Therapeutic targets: MTOR and related pathways
Explore this paper's citation graph
Summary
Clinical trial results show that mTOR inhibitors are well tolerated and may induce prolonged stable disease and tumor regressions in cancer patients and future research should evaluate optimal, schedule, patient selection, and combination strategies for this novel class of agents.
- Type
- article
- Published
- 2006-08-30
- Cited by
- 209
- References
- 93
- Access
- Open access
- OpenAlex
- https://openalex.org/W16969122
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:28508383
Keywords
Cyperus rotundus, Crop, Residual, Cyperus, Agronomy
References
- Cyclin D1 Expression Mediated by Phosphatidylinositol 3-Kinase through mTOR-p70S6K-Independent Signaling in Growth Factor-Stimulated NIH 3T3 Fibroblasts
- Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells.
- Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
- Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
- Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor
- Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
- Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy.
- CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
- Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
- Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
- Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
- Reversing Drug Resistance In Vivo
- Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice
- 411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials
- Inhibition of Mammalian Target of Rapamycin Activates Apoptosis Signal-regulating Kinase 1 Signaling by Suppressing Protein Phosphatase 5 Activity*
- Translation Factor eIF4E Rescues Cells from Myc-dependent Apoptosis by Inhibiting Cytochromec Release*
- Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
- mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.
- Restraining PI3K: mTOR signalling goes back to the membrane.
Cited by
- Phase I study of everolimus in pediatric patients with refractory solid tumors.
- Hypoxia-induced hypomyelination in the developing brain is mammalian target of rapamycin-4E-binding protein-1 signaling dependent
- Novel therapeutic targets.
- Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.
- Bioluminescent mouse models of prostate cancer progression and therapy
- Caracterização do perfil de expressão de MMPs e de seus inibidores, TIMPs e Reck, em linhagens representativas dos diferentes estágios de progressão do melanona humano
- Strategies to sensitize bladder cancer cells to small molecule inhibitors targeting the PI3K pathway
- Evaluation von mTOR und STAT5b als potentielle Zielstrukturen zur Behandlung des duktalen Adenokarzinom des Pankreas
- Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration.
- Regulation Of Membrane-Type 1 Matrix Metalloproteinase In Prostate Cancer
- Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population
- Pharmacokinetics, Pharmacodynamics, and Formulation Development of Hydrophobic Xenobiotics
- Investigating the cancer stem cell hypothesis in canine tumours
- Brassinin Induces Apoptosis in PC‐3 Human Prostate Cancer Cells through the Suppression of PI3K/Akt/mTOR/S6K1 Signaling Cascades
- Hypoxia as a target for drug combination therapy of liver cancer
- High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study.
- Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging
- Genetics of melanoma tumorigenesis
- Optimierung der Therapie des metastasierten Mammakarzinoms unter besonderer Berücksichtigung des Pi3K/Akt/mTOR-Signaltransduktionswegs
- Oncogenetics of melanoma: basis for molecular diagnostics and therapy